| Technology based on over two decades of research and experience.
Stemedica’s technology is based on the same vision of the company – to operate with a standard of excellence and a drive for results. Stemedica Cell Technologies, Incorporated utilizes proprietary and patented technology in its manufacturing processes. The technology is based on over 20 years of research and innovation and is implemented with a focus on compliance, efficacy and biosafety.
Stemedica uses only adult stem cell for its adult stem cell product line. Its adult stem cell products are manufactured through a proprietary cell processing platform. The objective of the platform is to create products with immuno tolerance and the highest chance of acceptance by the recipient system. The adult stem cell manufacturing process at Stemedica results in adult stem cells that are clearly differentiated in their ability to be tissue independent, pure via a singular isolation process, expanded in a serum free medium, and specially preserved.
Stemedica incorporates manufacturing processes that follow international Good Manufacturing Practice (“cGMP”) and current Good Laboratory Practices (“cGLP”) guidelines. The technology provides for immediate deployment of adult stem cells with highest levels of purity. Stemedica's manufacturing process is not limited by the source of adult stem cells. The processes and the technology result in adult stem cell products with a high degree of impact, easy acceptance and resistance to rejection.
Conditions treated through Stemedica's proprietary adult stem cell technology include Stroke, Alzheimer’s, Parkinson’s, Spinal Cord Injury, Ischemic Head Trauma, Eye Disease, Burns, Scars, Skin Ulcers, and Vesico-Ureteral Reflux. Treatment using Stemedica's technology is provided through Licensed Treatment Centers. In the near term, Stemedica expects to become “tissue independent”. This will enable Stemedica to manufacture their adult stem cell products solely from Adult Stem Cell Master Cell Banks. These banks will store reserves of adult stems cells ready to be deployed to the Licensed Treatment Centers for immediate use in patient therapy.
As part of Stemedica's ongoing commitment to increasing possibilities, they will continue to team with strategic partners. The goal of the relationships will be to develop technologies that increase ability to use adult stem cell therapies for other diseases and conditions.
Stemedica's technology and proprietary adult stem cell processing platform is one vital part of their multi-modal approach to adult tem cell therapeutic development. |
